Member Info for akramms

30 Apr 2020

https://www.pilotenergy.com.au/sites/pilotenergy.com.au/files/asx-announcements/6977475.pdf

https://www.pilotenergy.com.au/sites/pilotenergy.com.au/files/asx-announcements/6969235.pdf

Yesterday, we had a Price Monitoring Extension RNS, which is strange as there was only 2 trades

and only 10,908 shares traded, correct less than £50.

Weird thing is last trade or 2nd trade was 100, this must have been a stock code, as I believe the RNS mean there is someone buying in the back.

Pilot Energy and Key Petroleum required to get permit renewal before Red Emperor have the option to get 70% of oil play in North Perth Basin.

The status of the Permit has now changed to 'Offer', after last few months under it was 'under assessment' / 'Joint Authority for Decision'
https://neats.nopta.gov.au/ApprovalTracking?type=All&publicStatusId=14

Permit Approval is now the final stage

Which will give RMP to acquire 70% of perth basin oil play for A$500,000.

Last month RMP had cash of a$4.7m
Current MC £1.7m

https://www.lse.co.uk/rns/RMP/quarterly-activities-and-cashflow-report-2jbwq9l55gi11z7.html

30 Mar 2020

Recent share issues were at 5.25p for deemed payment of £420,000 for 8,000,000 shares, this is a premium of more than 1300% compared to the current price at that time of 0.004p. This is equivalent to paying £32,000 at 0.004p for 8,000,000 shares compared to the actual value of £420,000. If they had issues at current price for deemed payment of £420,000, they would have issues 13 times more shares 104000000, but instead only issued 8,000,000 at 5.25p 1300% premium.

In light of the progress and pursuant to the agreement for Kibo to consolidate full ownership of Bordersley by acquiring all of the original MED vendors, St' Anderton on Vaal Limited ('St' Anderton'), direct and indirect interests in Bordersley (see RNS dated 26 June 2019), the Company will now make a further and final payment of 8,000,000 shares in Kibo to St' Anderton, at a deemed issue price of 5.25 pence per share.

https://www.lse.co.uk/rns/KIBO/issue-of-shares-to-service-providers-and-contractors-93fekyy1aby279c.html

Another 11 solar mini-grids for Mozambique

Mozambican electricity access body the Fundo de Energia (Funae) has issued a request for expressions of interest to seek consultants to draft feasibility studies and project outlines for 11 solar mini grids.

The agency said the studies will be backed by the World Bank’s Energy for All program, which is being administered in Mozambique by Funae and state-owned utility Electricidade de Moçambique (EDM). Consultants have until May 19 to submit expressions of interest.

“The off-grid component will focus on supporting the electrification of areas where electricity supply through mini-grids represents the least-cost option from a country perspective,” said Funae in the tender document.

pv-magazine.com/2020/05/04/another-11-solar-mini-grids-for-mozambique/

Kibo Market Cap £4.45m
Shares in Issue: 1,272,272,188
Current Price 0.35p

Kibo owns 42.13% of Katoro Gold
https://katorogold.com/investors/shareholder-information/

Katoro Market Cap £5.13
Shares in Issue: 228,222,129
Current Price: 2.25p

Kibo investment in Katoro, alone is worth £2.16m, this is a fact.

So your telling me all their power projects alone are worth £2.29m, Don't make me laugh. This is way undervalued.

I wonder, if they've expanded their land holding for this very reason.

https://www.afrik21.africa/en/mozambique-funae-seeks-consultants-for-solar-mini-grids-projects/

The Mozambique Energy Fund (FUNAE) has just launched a call for expressions of interest for the recruitment of consultants. The consultants will be required to prepare feasibility studies and project outlines for 11 photovoltaic mini-grids. Tenderers have until May 19, 2020 to submit their proposals.

The government of Mozambique is increasing the number of electrification projects in the country. Following the call for tenders launched in March 2020 for the construction of five solar mini-hybrid grids in the provinces of Zambézie and Nampula, another project for 11 photovoltaic mini-grids is in the pipeline. In this context, the Mozambican Energy Fund (FUNAE) launched a call for proposals on the 23rd of April 2020 to benefit from the collaboration of consultants. The expected consultancy services include feasibility studies, preparation of tender documents and technical assistance during the call for tenders. Consultants have until May 19, 2020 to submit their applications.

According to energy fund, the feasibility studies will be supported by the World Bank’s “Energy for All” programme, which is administered in Mozambique by FUNAE and the state-owned Electricidade de Moçambique (EDM).

The solar mini-grids will be developed as public-private partnerships by independent power producers. Once commissioned, all electricity consumers powered by these facilities will become EDM customers.

The off-grid component will focus on supporting the electrification of areas where the supply of electricity through mini-solar grids is the cheapest option from the country’s point of view. It concerns 11 villages in the provinces of Niassa, Nampula, Tete, Sofala and Manica in Mozambique.

Hemogenyx (HEMO.L) A Covid-19 Cure Instead Of Just A Vaccine?

https://www.share-talk.com/hemogenyx-hemo-l-a-covid-19-cure-instead-of-just-a-vaccine/#gs.62cw3w

7 May 2020

Origo Partners Plc ("the Company")

Update re Liquidation Plans



Further to the Company's announcement of 24 December 2019, the Company notes that because of the global pandemic it has been unable to conclude its strategy of disposing of the Company's remaining assets and placing the Company in liquidation. The Company expects that when the current situation changes so as to enable the Company to conclude this strategy, the Company will so inform the market. Further announcements will be made in due course.

So expect something Today or Tomorrow.

http://ir.motifbio.com/news-releases/news-release-details/motif-bio-corporate-update

15 Nov 2017 Motif Bio secures up to US$20 million debt financing
https://1v6gj215h9gy3y4dgh3it40h-wpengine.netdna-ssl.com/wp-content/uploads/2017/11/20171115_MTFB-Hercules-debt-financing-PRwbk.pdf

28 Jan 2020 Agreement with Hercules Capital, Inc
The Company and its wholly owned subsidiary, Motif BioSciences Inc. (“Motif Inc”), have entered into a loan Amendment and Release agreement with Hercules Capital Inc. ("Hercules"), the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules (the “Hercules Agreement”).

Pursuant to the terms of the Hercules Agreement:

Hercules is relinquishing the loan guarantee provided by the Company and relieving Motif Bio plc of any future obligations to Hercules related to the November 2017 Hercules Loan to Motif Inc (the “Loan Agreement”).
Motif Inc. has granted Hercules a perfected security interest in all of its intellectual property.
To facilitate the wind down of Motif Inc. and potential sale of iclaprim related assets, Hercules has agreed with Motif Inc. to certain forbearance provisions under the Loan Agreement through to June 2020.
The terms of the Hercules Agreement are effective immediately, except for provisions of a release that relate to the pledge of Motif Bio’s interest in Motif Inc. which will become effective no later than 10 May 2020, being approximately 100 days after Hercules’s security interest in all of the intellectual property of Motif Inc. is perfected, provided that no voluntary or involuntary bankruptcy filing has occurred with respect to Motif Bio or Motif Inc.

1. Christopher (Chris) Wardhaugh
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.

Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.

2. 1st May 2019 MOTIF BIO SIGNS AGREEMENT WITH LAMELLAR BIOMEDICAL
Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar’s patented LAMELLASOME™ technology. Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar’s LAMELLASOME™ candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

3. Lamellar Biomedical launches program designed to prevent the severe respiratory effects of COVID-19, using its unique LAMELLASOME™ Technology.
https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html

MOTIF BIO SIGNS AGREEMENT WITH LAMELLAR BIOMEDICAL

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar’s patented LAMELLASOME™ technology. Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar’s LAMELLASOME™ candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

http://ir.motifbio.com/news-releases/news-release-details/motif-bio-signs-agreement-lamellar-biomedical

Placing to occur on 11 May

New WhatsApp chatbot unleashes power of worldwide fact-checking organizations to fight COVID-19 misinformation on the platform

https://www.poynter.org/fact-checking/2020/poynters-international-fact-checking-network-launches-whatsapp-chatbot-to-fight-covid-19-misinformation-leveraging-database-of-more-than-4000-hoaxes/

Closer to home, advertising agency M&C Saatchi’s recent webinar 2020 2.0 Back to the ‘new’ normal, shared compelling insights into how brands can stay relevant with clear purpose, enriching experiences and tangible value with an overarching message that brands that show up to help during the pandemic are the ones consumers will continue to want to engage with and support post lockdown when forced isolation fades from view.

This includes brands that work hard to deliver news and reporting that is verifiable and trusted, whether the news of the day is depressing or uplifting. News is, after all, trusted to inform and engage.

https://www.bizcommunity.com/Article/196/12/203384.html

https://www.hollywoodinsider.com/infotagion-disinformation-coronavirus/